Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2018
Price : $35 *
At a glance
- Drugs Omalizumab (Primary) ; Prednisone
- Indications Interstitial nephritis
- Focus Pharmacodynamics
- 04 Dec 2018 Planned End Date changed from 1 Dec 2018 to 28 Dec 2018.
- 04 Dec 2018 Planned primary completion date changed from 1 Sep 2018 to 28 Sep 2018.
- 04 Dec 2018 Status changed from recruiting to withdrawn prior to enrolment.